Repligen Aktie

Repligen ab 0 Euro bei Finanzen invest ordern (zzgl. Spreads)

WKN: 870980 / ISIN: US7599161095

<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
<
Aktion
Portfolio
Watchlist
>
05.11.2026 17:30:01

Repligen: 3 Key Takeaways for Long-Term Investors

On its third-quarter 2026 earnings call, held on Oct. 27, 2026, Repligen (NASDAQ:RGEN) announced record quarterly revenue of over $209 million as bioprocessing demand recovered. The bioprocess equipment manufacturer is expanding into high-growth cell therapy while securing long-term service contracts that lock in recurring demand. Three things management said stand out.

Repligen closed its purchase of BioLife, a cell therapy tools provider, to capture share in advanced treatments. Management expects the unit to generate $24 million in revenue during the fourth quarter.

While capital equipment revenue lagged, demand for bioprocessing machinery rebounded as customers placed new orders. These commitments build a multi-year backlog that sets up sales growth for 2027.

Continue reading

Analysen zu Repligen Corp.

mehr Analysen
Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Repligen Corp. 149,55 -5,71% Repligen Corp.